UBS Maintains Buy on HCA Healthcare, Raises Price Target to $438
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok maintains a Buy rating on HCA Healthcare and raises the price target from $405 to $438.
August 14, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Andrew Mok maintains a Buy rating on HCA Healthcare and raises the price target from $405 to $438.
The raised price target and maintained Buy rating from a reputable analyst at UBS is likely to positively impact HCA Healthcare's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100